Navigation Links
Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
Date:10/19/2007

ositive physician

reception for the Quill(TM) SRS product launch, we have

accelerated our investments in sales and marketing, completed our

hiring plans ahead of our original schedule, and will continue to

invest research and development resources to expand the Quill(TM)

SRS product line, with the goal of offering approximately 40

Quill(TM) SRS SKUs by year-end.

- Our full year 2007 outlook for certain expenses, including selling,

general and administrative and research and development expenses,

remains consistent with ranges as previously communicated, with

increases in sales and marketing related expenses as compared to the

upper end of the range a possibility. This outlook is inclusive of

investments in the second half of 2007 relating to:

- Sales force expansion, product launch and market development

initiatives for Quill(TM) SRS and our interventional business;

- Launch preparation activities related to our HemoStream(TM)

dialysis catheter product line, which recently received regulatory

approval one quarter in advance of our original expectations;

- The acceleration of clinical trial activities relating to our

Vascular Wrap(TM) product candidate in the U.S.;

- EU product launch and U.S. clinical trial activities relating to

our Bio-Seal(TM) lung biopsy product line.

- As a result of the revenue delays and the decision to maintain

investment in critical programs, we are updating our full year 2007

Adjusted EBITDA outlook range to $47 million to $50 million from the

previously stated $85 million to $95 million. Excluding research and

development expenses, the significant majority of which are

discretionary and relate primarily to our Pharmaceutical Technologi
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... longer-term toxicology studies for its newly developed Bruton,s ... RA, have been completed. The results of these ... Food and Drug Administration. The feedback received from ... the ongoing first-in-human study. Additional preclinical work is ...
(Date:2/27/2015)... ADELAIDE, Australia , Feb. 27, 2015 ... data from the DisrupTOR-1 trial of BNC105 in patients ... Symposium in Orlando, Florida . The ... of the City of Hope Comprehensive Cancer Center ... presentation. The new data identifies Ferritin ...
(Date:2/27/2015)... --  PureTech , a science and technology R&D company ... technologies in the healthcare sector, announced today the appointment ... of the Board of Directors of Sanofi, to its ... a pleasure to know Chris for many years and ... together more closely now," said Dr. Robert Langer ...
(Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... WASHINGTON, June 15 Congressional Quarterly presents a 360-degree ... of follow-on versions of biotech drugs. This CQ Forum ... interest groups, and leading researchers regarding the complex structures ... possible? Will the availability of these products save money ...
... ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) ... of shares of convertible preferred stock pursuant to a registered ... of approximately $2 million. The preferred stock is convertible into ... investor at a price of $0.1105 per share. , ...
... Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), ... oncology, today reported that patient follow-up in the open-label ... in benign prostatic hyperplasia (BPH) with its lead endocrinology ... the end of this week. Therefore, data analysis and ...
Cached Biology Technology:ADVENTRX Pharmaceuticals Announces Closing of Financing 2ADVENTRX Pharmaceuticals Announces Closing of Financing 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 2AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 3AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 4AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule 5
(Date:2/5/2015)... --  Epic Sciences , a precision diagnostics company dedicated to ... Prahalad , Ph.D., president and CEO, is scheduled to present ... Silicon Valley, which is taking place at the Computer History ... January 26-28, 2015. Dr. Prahalad will give ... year, Epic Sciences was a finalist in the PMWC,s Most ...
(Date:2/5/2015)... 28, 2015 Research and Markets ... the "Global Biometrics Market (2014-2020): Market Forecast ... report to their offering. , ... is anticipated to overtake ... increasing government spending towards IT security, government biometric ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry ... new website design. "When we launched FindBiometrics 12 ... Peter O,Neill , founder and CEO of FindBiometrics. "Now it,s ... from the key players on a very broad scale.  We ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... Researchers from the University of Illinois at Chicago have ... role in breaking down and inhibiting the formation of ... was published online this week in Nature Cell ... specialized cells are "recruited" to the wound site that ...
... and watched electrons flow through them, proving that single-molecule ... nanoscale science experiments. The finding, reported in the ... probes the effects of strong electron interactions that can ... size limit--single-molecule devices. The work resulted in the first ...
... National Eye Institute (NEI), part of the National Institutes ... translate molecular and genetic approaches from the laboratory to ... director Francis S. Collins, M.D., Ph.D., will deliver a ... feature discussions about cutting-edge treatment strategies as well as ...
Cached Biology News:Researchers discover mechanism that limits scar formation 2Stretching molecules yields new understanding of electricity 2National Eye Institute hosts Translational Research and Vision Symposium 2
... Terminal deoxynucleotidyl transferase (TdT) is an ... in cortical thymocytes and minor subpopulation of ... enzyme and increased numbers of TdT cells ... lymphoblastic leukaemias and lymphomas. Presence of TdT ...
Request Info...
... is a fast and efficient ... Its high capacity and reliable design ... walk away time than typical stackers. ... set-up make for a seamless and ...
... MLF1 Interacting Protein/PBIP1 (phospho T78) ( ... Antigen: Synthetic ... 73-83 of Human MLF1 Interacting Protein ... 359815 Swiss ...
Biology Products: